Coherus Oncology: The Catalyst Rich Period Is Here (NASDAQ:CHRS)
· seekingalpha.com
CHRS faces key H2’26–H1’27 catalysts with tagmokitug/casdozokitug readouts and rising Loqtorzi sales—plus CCR8 data upside. Click here to read.
Coherus Oncology ( CHRS ) has not experienced a sustained run-up, despite the fact the company is approaching a catalyst-rich period. Given CHRS had five or mor...